

# Kathleen Claes

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7584033/publications.pdf>

Version: 2024-02-01

163  
papers

9,974  
citations

28274

55  
h-index

43889

91  
g-index

174  
all docs

174  
docs citations

174  
times ranked

14884  
citing authors

#	ARTICLE	IF	CITATIONS
1	Breast-Cancer Risk in Families with Mutations in <i>PALB2</i> . New England Journal of Medicine, 2014, 371, 497-506.	27.0	745
2	Association of Type and Location of <i>BRCA1</i> and <i>BRCA2</i> Mutations With Risk of Breast and Ovarian Cancer. JAMA - Journal of the American Medical Association, 2015, 313, 1347.	7.4	390
3	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, 2017, 49, 680-691.	21.4	356
4	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nature Genetics, 2017, 49, 1767-1778.	21.4	289
5	Cancer Risks Associated With Germline <i>PALB2</i> Pathogenic Variants: An International Study of 524 Families. Journal of Clinical Oncology, 2020, 38, 674-685.	1.6	270
6	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. Nature Genetics, 2020, 52, 572-581.	21.4	265
7	Genome-Wide Association Study in <i>BRCA1</i> Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk. PLoS Genetics, 2013, 9, e1003212.	3.5	244
8	Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. Journal of the National Cancer Institute, 2017, 109, .	6.3	242
9	Mutational spectrum in a worldwide study of 29,700 families with <i>BRCA1</i> or <i>BRCA2</i> mutations. Human Mutation, 2018, 39, 593-620.	2.5	224
10	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nature Genetics, 2015, 47, 164-171.	21.4	221
11	Fluid Status in Peritoneal Dialysis Patients: The European Body Composition Monitoring (EuroBCM) Study Cohort. PLoS ONE, 2011, 6, e17148.	2.5	216
12	Polymorphisms in base-excision repair and nucleotide-excision repair genes in relation to lung cancer risk. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2007, 631, 101-110.	1.7	194
13	<i>PALB2</i> , <i>CHEK2</i> and <i>ATM</i> rare variants and cancer risk: data from COGS. Journal of Medical Genetics, 2016, 53, 800-811.	3.2	174
14	Common Breast Cancer Susceptibility Alleles and the Risk of Breast Cancer for <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers: Implications for Risk Prediction. Cancer Research, 2010, 70, 9742-9754.	0.9	169
15	Prediction of Breast and Prostate Cancer Risks in Male <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers Using Polygenic Risk Scores. Journal of Clinical Oncology, 2017, 35, 2240-2250.	1.6	152
16	Genotype-Phenotype Correlation in NF1: Evidence for a More Severe Phenotype Associated with Missense Mutations Affecting NF1 Codons 844â€“848. American Journal of Human Genetics, 2018, 102, 69-87.	6.2	144
17	High Incidence of Noonan Syndrome Features Including Short Stature and Pulmonic Stenosis in Patients carrying NF1 Missense Mutations Affecting p.Arg1809: Genotypeâ€“Phenotype Correlation. Human Mutation, 2015, 36, 1052-1063.	2.5	143
18	Spectrum of single- and multiexon NF1 copy number changes in a cohort of 1,100 unselected NF1 patients. Genes Chromosomes and Cancer, 2006, 45, 265-276.	2.8	129

#	ARTICLE	IF	CITATIONS
19	Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. <i>Nature Genetics</i> , 2016, 48, 374-386.	21.4	125
20	Chromosomal radiosensitivity in breast cancer patients with a known or putative genetic predisposition. <i>British Journal of Cancer</i> , 2002, 87, 1379-1385.	6.4	122
21	Glomus Tumors in Neurofibromatosis Type 1: Genetic, Functional, and Clinical Evidence of a Novel Association. <i>Cancer Research</i> , 2009, 69, 7393-7401.	0.9	122
22	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. <i>Nature Genetics</i> , 2020, 52, 56-73.	21.4	120
23	Radiation-induced damage to normal tissues after radiotherapy in patients treated for gynecologic tumors: Association with single nucleotide polymorphisms in XRCC1, XRCC3, and OGG1 genes and in vitro chromosomal radiosensitivity in lymphocytes. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 62, 1140-1149.	0.8	114
24	Acute Normal Tissue Reactions in Head-and-Neck Cancer Patients Treated With IMRT: Influence of Dose and Association With Genetic Polymorphisms in DNA DSB Repair Genes. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 73, 1187-1195.	0.8	113
25	Rapid detection of VHL exon deletions using real-time quantitative PCR. <i>Laboratory Investigation</i> , 2005, 85, 24-33.	3.7	102
26	The Exon 13 Duplication in the BRCA1 Gene Is a Founder Mutation Present in Geographically Diverse Populations. <i>American Journal of Human Genetics</i> , 2000, 67, 207-212.	6.2	100
27	Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. <i>Human Molecular Genetics</i> , 2009, 18, 4442-4456.	2.9	99
28	Comparison of mRNA Splicing Assay Protocols across Multiple Laboratories: Recommendations for Best Practice in Standardized Clinical Testing. <i>Clinical Chemistry</i> , 2014, 60, 341-352.	3.2	95
29	Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. <i>Nature Communications</i> , 2016, 7, 11375.	12.8	93
30	The genetic basis of undiagnosed muscular dystrophies and myopathies. <i>Neurology</i> , 2016, 87, 71-76.	1.1	92
31	Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. <i>Nature Communications</i> , 2019, 10, 1741.	12.8	90
32	Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. <i>Breast Cancer Research</i> , 2016, 18, 15.	5.0	88
33	Shared heritability and functional enrichment across six solid cancers. <i>Nature Communications</i> , 2019, 10, 431.	12.8	88
34	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. <i>Genetics in Medicine</i> , 2020, 22, 1653-1666.	2.4	82
35	Clinical spectrum of individuals with pathogenic <i>F1</i> missense variants affecting p.Met1149, p.Arg1276, and p.Lys1423: genotype-phenotype study in neurofibromatosis type 1. <i>Human Mutation</i> , 2020, 41, 299-315.	2.5	80
36	Differentiating pathogenic mutations from polymorphic alterations in the splice sites of BRCA1 and BRCA2. <i>Genes Chromosomes and Cancer</i> , 2003, 37, 314-320.	2.8	78

#	ARTICLE	IF	CITATIONS
37	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. <i>Nature Communications</i> , 2016, 7, 12675.	12.8	78
38	BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv315.	6.3	77
39	DNA Diagnostics of Hereditary Hearing Loss: A Targeted Resequencing Approach Combined with a Mutation Classification System. <i>Human Mutation</i> , 2016, 37, 812-819.	2.5	76
40	BRCA2 Hypomorphic Missense Variants Confer Moderate Risks of Breast Cancer. <i>Cancer Research</i> , 2017, 77, 2789-2799.	0.9	75
41	A Homozygous MSH6 Mutation in a Child with Café-au-Lait Spots, Oligodendroglioma and Rectal Cancer. <i>Familial Cancer</i> , 2002, 3, 123-127.	1.9	74
42	Leiden open variation database of the MUTYH gene. <i>Human Mutation</i> , 2010, 31, 1205-1215.	2.5	72
43	Rapid and Sensitive Detection of BRCA1/2 Mutations in a Diagnostic Setting: Comparison of Two High-Resolution Melting Platforms. <i>Clinical Chemistry</i> , 2008, 54, 982-989.	3.2	65
44	Next generation sequencing on patients with LGMD and nonspecific myopathies: Findings associated with ANO5 mutations. <i>Neuromuscular Disorders</i> , 2015, 25, 533-541.	0.6	65
45	Chromosomal radiosensitivity in BRCA1 and BRCA2 mutation carriers. <i>International Journal of Radiation Biology</i> , 2004, 80, 745-756.	1.8	64
46	Spectrum and characterisation of BRCA1 and BRCA2 deleterious mutations in high-risk Czech patients with breast and/or ovarian cancer. <i>BMC Cancer</i> , 2008, 8, 140.	2.6	64
47	Dominant-negative mutations in human IL6ST underlie hyper-IgE syndrome. <i>Journal of Experimental Medicine</i> , 2020, 217, .	8.5	64
48	A replication study confirms the association of TNFSF4 (OX40L) polymorphisms with systemic sclerosis in a large European cohort. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 638-641.	0.9	63
49	SVA retrotransposon insertion-associated deletion represents a novel mutational mechanism underlying large genomic copy number changes with non-recurrent breakpoints. <i>Genome Biology</i> , 2014, 15, R80.	9.6	63
50	Cancer Surveillance Guideline for individuals with PTEN hamartoma tumour syndrome. <i>European Journal of Human Genetics</i> , 2020, 28, 1387-1393.	2.8	63
51	Expanding the clinical phenotype of individuals with a 3-bp in-frame deletion of the NF1 gene (c.2970_2972del): an update of genotype-phenotype correlation. <i>Genetics in Medicine</i> , 2019, 21, 867-876.	2.4	62
52	A sensitive and specific diagnostic test for hearing loss using a microdroplet PCR-based approach and next generation sequencing. <i>American Journal of Medical Genetics, Part A</i> , 2013, 161, 145-152.	1.2	61
53	A multicentric, international matched pair analysis of body composition in peritoneal dialysis versus haemodialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 2620-2628.	0.7	61
54	Common variants associated with breast cancer in genome-wide association studies are modifiers of breast cancer risk in BRCA1 and BRCA2 mutation carriers. <i>Human Molecular Genetics</i> , 2010, 19, 2886-2897.	2.9	60

#	ARTICLE	IF	CITATIONS
55	Massive parallel amplicon sequencing of the breast cancer genes BRCA1 and BRCA2: opportunities, challenges, and limitations. <i>Human Mutation</i> , 2011, 32, 335-344.	2.5	58
56	TGF $\beta$ 1 polymorphisms and late clinical radiosensitivity in patients treated for gynecologic tumors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 65, 1240-1248.	0.8	57
57	Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research</i> , 2014, 16, 3416.	5.0	57
58	TIM3+ TRBV11-2 T cells and IFN $\gamma$ signature in patrolling monocytes and CD16+ NK cells delineate MIS-C. <i>Journal of Experimental Medicine</i> , 2022, 219, .	8.5	57
59	Comparison of microsatellite instability detection by immunohistochemistry and molecular techniques in colorectal and endometrial cancer. <i>Scientific Reports</i> , 2021, 11, 12880.	3.3	55
60	A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. <i>Cancer Research</i> , 2018, 78, 5419-5430.	0.9	54
61	Polymorphisms in nonhomologous end-joining genes associated with breast cancer risk and chromosomal radiosensitivity. <i>Genes Chromosomes and Cancer</i> , 2008, 47, 137-148.	2.8	51
62	The BRCA1 c. 5096G>A p.Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA consortium. <i>Journal of Medical Genetics</i> , 2018, 55, 15-20.	3.2	50
63	Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants. <i>JAMA Oncology</i> , 2020, 6, 1218.	7.1	48
64	Polymorphisms in the lectin pathway genes as a possible cause of early chronic <i>Pseudomonas aeruginosa</i> colonization in cystic fibrosis patients. <i>Human Immunology</i> , 2012, 73, 1175-1183.	2.4	47
65	DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. <i>PLoS Genetics</i> , 2014, 10, e1004256.	3.5	47
66	BRCA1 and BRCA2 germline mutation spectrum and frequencies in Belgian breast/ovarian cancer families. <i>British Journal of Cancer</i> , 2004, 90, 1244-1251.	6.4	46
67	Questioning the Pathogenic Role of the GLA p.Ala143Thr "Mutation" in Fabry Disease: Implications for Screening Studies and ERT. <i>JIMD Reports</i> , 2012, 8, 101-108.	1.5	44
68	Mutation analysis of RAD51D in non-BRCA1/2 ovarian and breast cancer families. <i>British Journal of Cancer</i> , 2012, 106, 1460-1463.	6.4	43
69	Flexible, Scalable, and Efficient Targeted Resequencing on a Benchtop Sequencer for Variant Detection in Clinical Practice. <i>Human Mutation</i> , 2015, 36, 379-387.	2.5	43
70	Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women. <i>Breast Cancer Research</i> , 2016, 18, 112.	5.0	42
71	BRCA1, BRCA2 and PALB2 mutations and CHEK2 c.1100delC in different South African ethnic groups diagnosed with premenopausal and/or triple negative breast cancer. <i>BMC Cancer</i> , 2015, 15, 912.	2.6	41
72	Practical Tools to Implement Massive Parallel Pyrosequencing of PCR Products in Next Generation Molecular Diagnostics. <i>PLoS ONE</i> , 2011, 6, e25531.	2.5	40

#	ARTICLE	IF	CITATIONS
73	Association of Genomic Domains in <i>BRCA1</i> and <i>BRCA2</i> with Prostate Cancer Risk and Aggressiveness. <i>Cancer Research</i> , 2020, 80, 624-638.	0.9	39
74	Pathological splice mutations outside the invariant AG/GT splice sites of <i>BRCA1</i> exon 5 increase alternative transcript levels in the 5' end of the <i>BRCA1</i> gene. <i>Oncogene</i> , 2002, 21, 4171-4175.	5.9	35
75	Assessing Associations between the AURKA-HMMR-TPX2-TUBG1 Functional Module and Breast Cancer Risk in <i>BRCA1/2</i> Mutation Carriers. <i>PLoS ONE</i> , 2015, 10, e0120020.	2.5	34
76	Jaffe "Campanacci syndrome, revisited: detailed clinical and molecular analyses determine whether patients have neurofibromatosis type 1, coincidental manifestations, or a distinct disorder. <i>Genetics in Medicine</i> , 2014, 16, 448-459.	2.4	33
77	Mate pair sequencing for the detection of chromosomal aberrations in patients with intellectual disability and congenital malformations. <i>European Journal of Human Genetics</i> , 2014, 22, 652-659.	2.8	32
78	Non Coding RNA Molecules as Potential Biomarkers in Breast Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2015, 867, 263-275.	1.6	32
79	Transcriptome-wide association study of breast cancer risk by estrogen receptor status. <i>Genetic Epidemiology</i> , 2020, 44, 442-468.	1.3	32
80	Two-tier approach for the detection of alpha-galactosidase A deficiency in a predominantly female haemodialysis population. <i>Nephrology Dialysis Transplantation</i> , 2007, 23, 294-300.	0.7	31
81	Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. <i>Breast Cancer Research</i> , 2016, 18, 64.	5.0	31
82	Functional redundancy of exon 12 of <i>BRCA2</i> revealed by a comprehensive analysis of the c.6853A>G (p.I2285V) variant. <i>Human Mutation</i> , 2009, 30, 1543-1550.	2.5	30
83	Height and Body Mass Index as Modifiers of Breast Cancer Risk in <i>BRCA1/2</i> Mutation Carriers: A Mendelian Randomization Study. <i>Journal of the National Cancer Institute</i> , 2019, 111, 350-364.	6.3	30
84	Prevalence of <i>BRCA1/2</i> mutations in sporadic breast/ovarian cancer patients and identification of a novel de novo <i>BRCA1</i> mutation in a patient diagnosed with late onset breast and ovarian cancer: implications for genetic testing. <i>Breast Cancer Research and Treatment</i> , 2012, 132, 87-95.	2.5	29
85	Variant Ataxia Telangiectasia: Clinical and Molecular Findings and Evaluation of Radiosensitive Phenotypes in a Patient and Relatives. <i>NeuroMolecular Medicine</i> , 2013, 15, 447-457.	3.4	29
86	Dealing with Pseudogenes in Molecular Diagnostics in the Next-Generation Sequencing Era. <i>Methods in Molecular Biology</i> , 2014, 1167, 303-315.	0.9	29
87	Benign retroperitoneal schwannoma presenting as colitis: A case report. <i>World Journal of Gastroenterology</i> , 2007, 13, 5521.	3.3	29
88	THE RATE OF GASTRIC EMPTYING DETERMINES THE TIMING BUT NOT THE EXTENT OF ORAL TACROLIMUS ABSORPTION: SIMULTANEOUS MEASUREMENT OF DRUG EXPOSURE AND GASTRIC EMPTYING BY CARBON-14-OCTANOIC ACID BREATH TEST IN STABLE RENAL ALLOGRAFT RECIPIENTS. <i>Drug Metabolism and Disposition</i> , 2004, 32, 1421-1425.	3.3	28
89	&lt;i>IRF6&lt;/i>; Screening of Syndromic and a priori Non-Syndromic Cleft Lip and Palate Patients: Identification of a New Type of Minor VWS Sign. <i>Molecular Syndromology</i> , 2010, 1, 67-74.	0.8	28
90	Characterization of the nonallelic homologous recombination hotspot PRS3 associated with type-3 <i>NF1</i> deletions. <i>Human Mutation</i> , 2012, 33, 372-383.	2.5	28

#	ARTICLE	IF	CITATIONS
91	The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer. <i>Npj Breast Cancer</i> , 2019, 5, 38.	5.2	28
92	The Zebrafish as an Emerging Model to Study DNA Damage in Aging, Cancer and Other Diseases. <i>Frontiers in Cell and Developmental Biology</i> , 2018, 6, 178.	3.7	28
93	Shallow whole-genome sequencing of plasma cell-free DNA accurately differentiates small from non-small cell lung carcinoma. <i>Genome Medicine</i> , 2020, 12, 35.	8.2	28
94	Mutation Analysis of the BRCA1 and BRCA2 Genes in the Belgian Patient Population and Identification of a Belgian Founder Mutation BRCA1 IVS5+3A>G. <i>Disease Markers</i> , 1999, 15, 69-73.	1.3	27
95	Combined effect of polymorphisms in Rad51 and Xrcc3 on breast cancer risk and chromosomal radiosensitivity. <i>Molecular Medicine Reports</i> , 2011, 4, 901-12.	2.4	27
96	Mitotic recombination of chromosome arm 17q as a cause of loss of heterozygosity of <i>NF1</i> in neurofibromatosis type 1-associated glomus tumors. <i>Genes Chromosomes and Cancer</i> , 2012, 51, 429-437.	2.8	27
97	Identification of recurrent type-2 <i>NF1</i> microdeletions reveals a mitotic nonallelic homologous recombination hotspot underlying a human genomic disorder. <i>Human Mutation</i> , 2012, 33, 1599-1609.	2.5	26
98	An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. <i>Breast Cancer Research</i> , 2015, 17, 61.	5.0	26
99	An international survey of surveillance schemes for unaffected BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2016, 157, 319-327.	2.5	26
100	Analysis of chromosomal radiosensitivity of healthy BRCA2 mutation carriers and non-carriers in BRCA families with the G2 micronucleus assay. <i>Oncology Reports</i> , 2017, 37, 1379-1386.	2.6	26
101	Increased chromosomal radiosensitivity in asymptomatic carriers of a heterozygous BRCA1 mutation. <i>Breast Cancer Research</i> , 2016, 18, 52.	5.0	25
102	Decoding NF1 Intragenic Copy-Number Variations. <i>American Journal of Human Genetics</i> , 2015, 97, 238-249.	6.2	24
103	Evaluation of RAD51C as cancer susceptibility gene in a large breast-ovarian cancer patient population referred for genetic testing. <i>Breast Cancer Research and Treatment</i> , 2012, 133, 393-398.	2.5	23
104	Polygenic risk modeling for prediction of epithelial ovarian cancer risk. <i>European Journal of Human Genetics</i> , 2022, 30, 349-362.	2.8	23
105	Mutation analysis of the BRCA1 and BRCA2 genes results in the identification of novel and recurrent mutations in 6/16 Flemish families with breast and/or ovarian cancer but not in 12 sporadic patients with early-onset disease. <i>Human Mutation</i> , 1999, 13, 256-256.	2.5	22
106	Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 308-316.	2.5	22
107	Genotyping of Frequent BRCA1/2 SNPs with Unlabeled Probes. <i>Journal of Molecular Diagnostics</i> , 2009, 11, 415-419.	2.8	21
108	Analysis of the Novel Fanconi Anemia Gene <i>SLX4</i> / <i>FANCP</i> in Familial Breast Cancer Cases. <i>Human Mutation</i> , 2013, 34, 70-73.	2.5	21



#	ARTICLE	IF	CITATIONS
109	Microsatellite instability in sporadic colon carcinomas has no independent prognostic value in a Belgian study population. <i>European Journal of Cancer</i> , 2008, 44, 2288-2295.	2.8	19
110	Genetic Testing and Clinical Management Practices for Variants in Non-BRCA1/2 Breast (and) Tumor Tissue for the Interpretation of Germline Mutant Alleles (ENIGMA) Clinical Working Group. <i>JCO Precision Oncology</i> , 2018, 2, 1-42.	3.0	19
111	Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. <i>British Journal of Cancer</i> , 2019, 121, 180-192.	6.4	19
112	A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. <i>Nature Communications</i> , 2021, 12, 1078.	12.8	19
113	Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores. <i>Journal of the National Cancer Institute</i> , 2022, 114, 109-122.	6.3	19
114	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. <i>Gynecologic Oncology</i> , 2016, 141, 386-401.	1.4	18
115	Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. <i>Breast Cancer Research and Treatment</i> , 2017, 161, 117-134.	2.5	18
116	Two-tier approach for the detection of alpha-galactosidase A deficiency in kidney transplant recipients. <i>Nephrology Dialysis Transplantation</i> , 2008, 23, 4044-4048.	0.7	17
117	Boosting care and knowledge about hereditary cancer: European Reference Network on Genetic Tumour Risk Syndromes. <i>Familial Cancer</i> , 2019, 18, 281-284.	1.9	17
118	The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant. <i>Genetics in Medicine</i> , 2021, 23, 1726-1737.	2.4	16
119	Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA). <i>British Journal of Cancer</i> , 2009, 101, 2048-2054.	6.4	15
120	BRCA1 and BRCA2 5' noncoding region variants identified in breast cancer patients alter promoter activity and protein binding. <i>Human Mutation</i> , 2018, 39, 2025-2039.	2.5	15
121	Long term response on Regorafenib in non-V600E BRAF mutated colon cancer: a case report. <i>BMC Cancer</i> , 2019, 19, 567.	2.6	15
122	Chromosomal radiosensitivity of breast cancer with a mutation. <i>Cancer Genetics and Cytogenetics</i> , 2005, 163, 106-112.	1.0	13
123	Palindrome-Mediated and Replication-Dependent Pathogenic Structural Rearrangements within the NF1 Gene. <i>Human Mutation</i> , 2014, 35, 891-898.	2.5	13
124	Extreme clustering of type-1 NF1 deletion breakpoints co-locating with G-quadruplex forming sequences. <i>Human Genetics</i> , 2018, 137, 511-520.	3.8	13
125	Shallow-depth sequencing of cell-free DNA for Hodgkin and diffuse large B-cell lymphoma (differential) diagnosis: a standardized approach with underappreciated potential. <i>Haematologica</i> , 2020, Online ahead of print, 0-0.	3.5	13
126	Evaluation of relative quantification of alternatively spliced transcripts using droplet digital PCR. <i>Biomolecular Detection and Quantification</i> , 2017, 13, 40-48.	7.0	12



#	ARTICLE	IF	CITATIONS
127	Accurate detection and quantification of epigenetic and genetic second hits in BRCA1 and BRCA2-associated hereditary breast and ovarian cancer reveals multiple co-acting second hits. <i>Cancer Letters</i> , 2018, 425, 125-133.	7.2	12
128	Diagnosis of Fanconi Anaemia by ionising radiation- or mitomycin C-induced micronuclei. <i>DNA Repair</i> , 2018, 61, 17-24.	2.8	12
129	Enhanced MCP-1 Release in Early Autosomal Dominant Polycystic Kidney Disease. <i>Kidney International Reports</i> , 2021, 6, 1687-1698.	0.8	12
130	Next Generation Sequencing to Determine the Cystic Fibrosis Mutation Spectrum in Palestinian Population. <i>Disease Markers</i> , 2015, 2015, 1-6.	1.3	11
131	Focus on 16p13.3 Locus in Colon Cancer. <i>PLoS ONE</i> , 2015, 10, e0131421.	2.5	11
132	The genetics of familial adenomatous polyposis (FAP) and MutYH-associated polyposis (MAP). <i>Acta Gastro-Enterologica Belgica</i> , 2011, 74, 421-6.	1.0	11
133	Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. <i>PLoS ONE</i> , 2016, 11, e0158801.	2.5	10
134	Multiple orbital neurofibromas, painful peripheral nerve tumors, distinctive face and marfanoid habitus: a new syndrome. <i>European Journal of Human Genetics</i> , 2012, 20, 618-625.	2.8	9
135	Accurate quantification of homologous recombination in zebrafish: brca2 deficiency as a paradigm. <i>Scientific Reports</i> , 2017, 7, 16518.	3.3	9
136	Joint Belgian recommendation on screening for DPD-deficiency in patients treated with 5-FU, capecitabine (and tegafur). <i>Acta Clinica Belgica</i> , 2021, , 1-7.	1.2	9
137	Pathogenic neurofibromatosis type 1 (NF1) RNA splicing resolved by targeted RNAseq. <i>Npj Genomic Medicine</i> , 2021, 6, 95.	3.8	9
138	Prostate cancer in Cowden syndrome: somatic loss and germline mutation of the PTEN gene. <i>Cancer Genetics</i> , 2011, 204, 224-225.	0.4	8
139	Prevalence of Germline Pathogenic Variants in Cancer Predisposing Genes in Czech and Belgian Pancreatic Cancer Patients. <i>Cancers</i> , 2021, 13, 4430.	3.7	8
140	Somatic mosaics in hereditary tumor predisposition syndromes. <i>European Journal of Medical Genetics</i> , 2021, 64, 104360.	1.3	8
141	Radiation-induced myosin IIA expression stimulates collagen type I matrix reorganization. <i>Radiotherapy and Oncology</i> , 2013, 108, 162-167.	0.6	7
142	Genetic Counselling and Testing for Hereditary Breast and Ovarian Cancer: The Gent(le) Approach. <i>Disease Markers</i> , 1999, 15, 191-195.	1.3	5
143	Thorough in silico and in vitro cDNA analysis of 21 putative BRCA1 and BRCA2 splice variants and a complex tandem duplication in BRCA2 allowing the identification of activated cryptic splice donor sites in BRCA2 exon 11. <i>Human Mutation</i> , 2018, 39, 515-526.	2.5	5
144	Germline Genetic Findings Which May Impact Therapeutic Decisions in Families with a Presumed Predisposition for Hereditary Breast and Ovarian Cancer. <i>Cancers</i> , 2020, 12, 2151.	3.7	5

#	ARTICLE	IF	CITATIONS
145	Myxoid hepatocellular adenoma, a rare variant of hepatocellular adenoma with distinct imaging features: A case report with immunohistochemical and molecular analysis and literature review. Clinics and Research in Hepatology and Gastroenterology, 2021, 45, 101478.	1.5	5
146	Twenty Years of BRCA1 and BRCA2 Molecular Analysis at MMCI – Current Developments for the Classification of Variants. Klinicka Onkologie, 2019, 32, 51-71.	0.3	5
147	An abnormally glycosylated isoform of erythropoietin in hemangioblastoma is associated with polycythemia. Clinica Chimica Acta, 2015, 438, 304-306.	1.1	3
148	Incorporating PARP-inhibitors into clinical routine: A tailored treatment strategy to tackle ovarian cancer. Acta Clinica Belgica, 2017, 72, 6-11.	1.2	3
149	Missing heritability in Bloom syndrome: First report of a deep intronic variant leading to pseudo-exon activation in the <i>BLM</i> gene. Clinical Genetics, 2021, 99, 292-297.	2.0	3
150	Application of an Ultrasensitive NGS-Based Blood Test for the Diagnosis of Early-Stage Lung Cancer: Sensitivity, a Hurdle Still Difficult to Overcome. Cancers, 2022, 14, 2031.	3.7	3
151	Objective assessment of nasality in Flemish adults with neurofibromatosis type 1. American Journal of Medical Genetics, Part A, 2011, 155, 2974-2981.	1.2	2
152	Lhermitte-Duclos disease with obstructive hydrocephalus: An illustrative case treated with endoscopic ventriculo-cisternostomy. Revue Neurologique, 2013, 169, 917-919.	1.5	2
153	Chromosomal radiosensitivity of triple negative breast cancer patients. International Journal of Radiation Biology, 2019, 95, 1507-1516.	1.8	2
154	Zebrafish as an in vivo screening tool to establish PARP inhibitor efficacy. DNA Repair, 2021, 97, 103023.	2.8	2
155	Breast-Cancer Risk in Families With Mutations in PALB2. Obstetrical and Gynecological Survey, 2014, 69, 659-660.	0.4	1
156	Timing of blood sampling for butyrylcholinesterase phenotyping in patients with prolonged neuromuscular block after mivacurium or suxamethonium. Acta Anaesthesiologica Scandinavica, 2021, 65, 182-187.	1.6	1
157	Dealing with Pseudogenes in Molecular Diagnostics in the Next Generation Sequencing Era. Methods in Molecular Biology, 2021, 2324, 363-381.	0.9	1
158	Midline nasal dermoid sinus cyst in basal cell naevus syndrome (BCNS or Gorlin syndrome): A case report and review. International Journal of Pediatric Otorhinolaryngology Extra, 2012, 7, 119-121.	0.1	0
159	Second hit landscape in BRCA1/2-associated breast cancer. Annals of Oncology, 2017, 28, i9.	1.2	0
160	Hereditary Syndromes and Pancreatic Cancer. , 2021, , 29-49.		0
161	Frequency of Participation in External Quality Assessment Programs Focused on Rare Diseases: Belgian Guidelines for Human Genetics Centers. JMIR Medical Informatics, 2021, 9, e27980.	2.6	0
162	Decreased DNA double-strand break repair and enhanced chromosomal radiosensitivity in irradiated non-tumorigenic human breast epithelial cells with a partial BRCA1 or BRCA2 knockdown. World Academy of Sciences Journal, 0, , .	0.6	0

#	ARTICLE	IF	CITATIONS
163	Atm deficient zebrafish model reveals conservation of the tumour suppressor function and a role in fertility. Genes and Diseases, 2023, 10, 381-384.	3.4	0